COVID-19: Beijing-based firm CNBG claims positive results in human-based vaccine trials

ST Staff
Monday, 29 June 2020

For the trial, CNBG developed and used an experimental shot with high-level of antibodies to inject into 1,120 healthy participants during it's 1/2 clinical trial phase. CNBG posted the information on WeChat, a social media platform without revealing too many details.

The Beijing-based, China National Biotec Group (CNBG) reported on Sunday that their coronavirus vaccine showed promising results after human test trials. According to reports, the group suggested the vaccine could be safe and effective.

For the trial, CNBG developed and used an experimental shot with high-level of antibodies to inject into 1,120 healthy participants during it's 1/2 clinical trial phase. CNBG posted the information on WeChat, a social media platform without revealing too many details.

Presently, China is the major front runner with eight vaccine candidates under human trials. Globally, in the race to develop a vaccine for COVID-19, there are over 100 projects under development and about 11 vaccine candidates are under clinical trials.

CNBC's Wuhan based unit used another COVID-19 vaccine candidate with high-level antibodies in participants during clinical trials after reviewing preliminary results.

It's important for any vaccine candidate to clear 'phase 3' and show effectiveness in human test in several participants.

On Tuesday, CNBC will run one of its vaccine candidate for Phase 3 trials in the United Arab Emirates.

Globally, more than half a million lives succumbed to the novel coronavirus. According to official reports, 5,00,390 deaths have been recorded since the outbreak of coronavirus. The overall COVID-19 case tally around the world stands at 10,099,576. The fast development of a COVID-19 vaccine to combat the fight against the virus is the need of the hour.

Another vaccine trial

Another such candidate, ChAdOx1 nCoV-19 vaccine under AstraZeneca licence is the first vaccine to enter the final stages of clinical trials. The plan of action for the next stage is to use ChAdOx1 nCoV-19 vaccine on 10,260 adults and children in the United Kingdom. Serum Institute of India (SII) is investing $100 million to develop and distribute one billion doses for India. The experimental vaccine is being developed by the University of Oxford and AstraZeneca Plc.

Related News

​ ​